Agios Pharmaceuticals (NASDAQ:AGIO) Lowered to Sell Rating by StockNews.com

Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Friday.

A number of other brokerages have also issued reports on AGIO. Leerink Partnrs lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Scotiabank boosted their target price on Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a “sector outperform” rating in a research report on Friday. Leerink Partners cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $60.00 to $56.00 in a report on Friday, September 27th. Royal Bank of Canada restated an “outperform” rating and issued a $55.00 price target on shares of Agios Pharmaceuticals in a research note on Friday. Finally, Raymond James reiterated an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $52.33.

Agios Pharmaceuticals Trading Up 1.0 %

NASDAQ:AGIO opened at $44.87 on Friday. The stock’s 50 day simple moving average is $44.62 and its 200-day simple moving average is $42.13. Agios Pharmaceuticals has a 12-month low of $20.40 and a 12-month high of $53.28. The firm has a market cap of $2.55 billion, a P/E ratio of -6.90, a PEG ratio of 0.47 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The firm had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. During the same period in the prior year, the firm posted ($1.51) earnings per share. The business’s quarterly revenue was up 28.4% compared to the same quarter last year. Research analysts forecast that Agios Pharmaceuticals will post 7.54 EPS for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In related news, CEO Brian Goff sold 11,091 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the transaction, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at $3,368,358. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Brian Goff sold 11,091 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the sale, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares of the company’s stock, valued at $988,346.74. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC purchased a new position in Agios Pharmaceuticals during the second quarter worth $37,000. Quest Partners LLC purchased a new stake in shares of Agios Pharmaceuticals in the second quarter valued at $40,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Agios Pharmaceuticals by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares during the last quarter. CWM LLC increased its position in Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,836 shares in the last quarter. Finally, North Star Asset Management Inc. purchased a new stake in Agios Pharmaceuticals during the 2nd quarter worth about $216,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.